Rani Therapeutics
RANI
28 hedge funds and large institutions have $29.1M invested in Rani Therapeutics in 2022 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 9 increasing their positions, 6 reducing their positions, and 0 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
50% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 6
17% more funds holding
Funds holding: 24 → 28 (+4)
1.44% less ownership
Funds ownership: 12.97% → 11.54% (-1.4%)
16% less capital invested
Capital invested by funds: $34.5M → $29.1M (-$5.42M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$910K |
| 2 |
TWA
TPB Wealth Advisors
San Antonio,
Texas
|
+$824K |
| 3 |
BlackRock
New York
|
+$568K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$494K |
| 5 |
CCM
Crossvault Capital Management
San Antonio,
Texas
|
+$164K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$185K |
| 2 |
JP Morgan Chase
New York
|
-$13.1K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$11.8K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$11.6K |
| 5 |
Osaic Holdings
Scottsdale,
Arizona
|
-$3.8K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Citigroup
New York
| $4K | -$517 | -45 | -11% |
|
27
Daiwa Securities Group
Tokyo,
Japan
| $1K | – | – | – |
|
RANI Hedge Fund Activity: Q2 2022 in Review
28 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Rani Therapeutics (RANI) for Q2 2022, worth a combined $29.1M — down 16% from $34.5M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new RANI positions and 0 closed out — a net gain of 4 holders — while 9 added to existing stakes and 6 trimmed.
The largest buyer was Millennium Management, adding an estimated $910K. The largest seller was Goldman Sachs, cutting an estimated $185K.
- 28 institutional investors held Rani Therapeutics (RANI) as of Q2 2022, up from 24 in Q1 2022.
- Funds reported $29.1M of Rani Therapeutics stock for Q2 2022, down 16% quarter-over-quarter.
- 4 funds opened new Rani Therapeutics positions in Q2 2022 and 0 closed out, a net change of +4 holders.
- The largest Rani Therapeutics buyer in Q2 2022 was Millennium Management, an estimated $910K added.
- The largest Rani Therapeutics seller in Q2 2022 was Goldman Sachs, an estimated $185K sold.
Based on aggregated 13F filings for Q2 2022.